Coenzyme Q10 Supplementation Improves Adipokine Profile In Dyslipidemic Individuals: A Randomized Controlled Trial

Background: Adipokines are peptides secreted mainly by adipose tissue, which have been demonstrated to be vital targets of metabolic diseases. However, the effect of coenzyme Q10 (CoQ10) on adipokines has not been well studied. Methods: We investigate the effect of CoQ10 intervention on adipokines in dyslipidemic patients. In this randomized, double-blinded, placebo-controlled trial, a number of 101 dyslipidemic individuals were administrated to 120 mg CoQ10 or placebo for 24 weeks. Anthropometric parameters, glucolipid profile, serum total adiponectin, leptin, and resistin were evaluated at baseline, week 12 and week 24. Results: CoQ10 significantly increased adiponectin at week 12 (380 ng/mL [SE, 101] ng/mL, p < 0.001) and had more increment at week 24 (611 ng/mL [SE, 126] ng/mL , p < 0.001). The increase of adiponectin was negative associated with decrease in HOMA-IR (r = -0.465, p = 0.001), TG (r = -0.297, p = 0.047), and LDL-c (r = -0.440, p = 0.002) at week 24 only in CoQ10 group. Resistin was reduced by CoQ10 only at week 24 (3.45 ng/mL [SE, 0.69] ng/mL, p < 0.001) compared with placebo group. Reduction of resistin was positively correlated with the change in HOMA-IR (r = 0.343, p = 0.021) and TG (r = 0.323, p = 0.030) at week 24 in CoQ10 group but not placebo group. Leptin was not influenced by CoQ10 treatment. Conclusions: Our study shows that CoQ10 ameliorates adipokines dysfunction in dyslipidemia patients in 24 weeks intervention, which suggests the beneficial effect of CoQ10 in modulating adipokine profile and metabolic disorders in dyslipidemic adults.Trial registration: ClinicalTrials.gov, NCT02407548. Registered on April 3, 2015, https://clinicaltrials.gov/ct2/show/NCT02407548.